# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.